PitchSend

Allurion SPAC Presentation Deck

A IDE for AUDACITY Trial Has Been Approved by FDA Enrollment begun in May 2022 Treatment Group (n= 250) Control Group (n = 250) °C WO | Co-Primary 50% responder rate Endpoints: (>5% TBWL) at 48 weeks 8 Open-label, sequential balloon 88 design is expected to boost weight loss and durability IDE- Investigational Device Exemption Balloon 1 W16 W24 Moderate Intensity Lifestyle Therapy Moderate Intensity Lifestyle Therapy M Break 3.0% total body weight loss (TBWL) superiority margin at 48 weeks Balloon 2 Conservative sample size and powering W40 W48 Break 48-week endpoint may open door to reimbursement 21

View entire presentation